Inquiry Basket
Loading ......
Filter By Product Search for
F5
F5 Full Name
coagulation factor V (proaccelerin, labile factor)
F5 Introduction
Understanding the biological role of coagulation-related genes is critical for researchers studying bleeding disorders, thrombosis, and even cancer biology. Coagulation factor V (F5) encodes a large plasma glycoprotein that functions as a key cofactor in the blood coagulation cascade, a tightly regulated process that prevents excessive bleeding while maintaining normal blood flow. In circulation, factor V is primarily synthesized in the liver and stored partially within platelet α-granules. Once activated to factor Va, it forms the prothrombinase complex together with factor Xa on phospholipid surfaces, dramatically accelerating the conversion of prothrombin into thrombin. Because thrombin generation represents a central step in clot formation, the activity and regulation of F5 are essential for maintaining hemostatic balance. For researchers and clinicians investigating coagulation disorders, the F5 gene represents a crucial molecular node linking genetic variation, regulatory signaling, and clinical outcomes.
Beyond its classical function in hemostasis, emerging studies suggest that F5 may also play roles in hormone-regulated cellular processes and cancer biology. Recent research has shown that F5 behaves as an estrogen-responsive gene in estrogen receptor–positive breast cancer cells. In models such as MCF-7 cells, exposure to estradiol significantly increases both F5 mRNA and protein expression, indicating that the gene can be directly regulated by estrogen receptor signaling. Mechanistic analyses have identified multiple estrogen receptor binding sites within the promoter region of the F5 gene, supporting the idea that hormonal signaling can modulate its transcription. Clinically, elevated F5 expression has been associated with shorter recurrence-free survival in patients with estrogen receptor–positive breast cancer, suggesting that this coagulation factor may contribute to tumor progression or tumor-associated coagulation pathways. These findings highlight a growing research interest in the intersection between coagulation biology and oncology, where F5 may serve not only as a hemostatic factor but also as a potential biomarker for disease prognosis.
Genetic and epigenetic alterations in the F5 gene are strongly associated with several coagulation disorders and thrombotic conditions, making it a frequent focus in clinical genetics and translational research. Mutations within F5 can cause congenital factor V deficiency, a rare bleeding disorder characterized by reduced clotting activity and symptoms such as mucosal bleeding, epistaxis, and prolonged bleeding after injury or surgery. Conversely, specific variants such as the well-known Factor V Leiden mutation increase the risk of thrombophilia by reducing the inactivation of factor Va by activated protein C. Large-scale variant databases have cataloged hundreds of F5 mutations, helping clinicians interpret genetic test results and understand their pathogenic significance. In addition to DNA sequence variants, epigenetic regulation also influences F5 expression; for example, reduced DNA methylation at certain CpG sites within the gene has been associated with increased expression and elevated thrombotic risk. Together, these discoveries demonstrate that F5 sits at the intersection of coagulation biology, genetics, and disease susceptibility, making it an important target for diagnostic research, biomarker development, and studies exploring the molecular mechanisms of thrombosis and bleeding disorders.
Alternate Names for F5
F5; coagulation factor V (proaccelerin, labile factor); FVL; PCCF; THPH2; RPRGL1; coagulation factor V; factor V Leiden; proaccelerin, labile factor; activated protein c cofactor; coagulation factor V jinjiang A2 domain; Coagulation factor V; Activated pr
Loading ......
